Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects

PURPOSE: Treatment for chronic lymphocytic leukemia (CLL) has changed dramatically with the approval of novel agents. Information regarding how patients and oncologists make trade-offs across attributes of novel therapies is limited. The purpose of this study was to understand how variations in attr...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Hannah, Ryan, Kellie, Wahlstrom, Svea K, Maculaitis, Martine C, Will, Oliver, Mulvihill, Emily, LeBlanc, Thomas W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837542/
https://www.ncbi.nlm.nih.gov/pubmed/33519195
http://dx.doi.org/10.2147/PPA.S289139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837542/
https://www.ncbi.nlm.nih.gov/pubmed/33519195
http://dx.doi.org/10.2147/PPA.S289139

Ejemplares similares